Terms: = Leukemia AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1
280 results:
1. Dachshund Homolog 1: Unveiling Its Potential Role in Megakaryopoiesis and
Lin GL; Chang HH; Lin WT; Liou YS; Lai YL; Hsieh MH; Chen PK; Liao CY; Tsai CC; Wang TF; Chu SC; Kau JH; Huang HH; Hsu HL; Sun DS
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542074
[TBL] [Abstract] [Full Text] [Related]
2. The effect of STAT1, miR-99b, and map2k1 in alcoholic liver disease (ALD) mouse model and hepatocyte.
Du H; Yu H; Zhou M; Hui Q; Hou Y; Jiang Y
Aging (Albany NY); 2024 Feb; 16(5):4224-4235. PubMed ID: 38431286
[TBL] [Abstract] [Full Text] [Related]
3. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
[TBL] [Abstract] [Full Text] [Related]
4. Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis.
Chang L; Lang M; Lin H; Cai H; Duan MH; Zhou DB; Cao XX
Leukemia; 2024 Apr; 38(4):803-809. PubMed ID: 38388646
[TBL] [Abstract] [Full Text] [Related]
5. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.
Roskoski R
Pharmacol Res; 2024 Feb; 200():107059. PubMed ID: 38216005
[TBL] [Abstract] [Full Text] [Related]
6. High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models.
Vuaroqueaux V; Musch A; Peille AL; Kelter G; Weichert L; Metz T; Hendriks HR; Fiebig HH
Cancer Res Commun; 2023 Oct; 3(10):2170-2181. PubMed ID: 37830744
[TBL] [Abstract] [Full Text] [Related]
7. The clinical and molecular taxonomy of t(14;18)-negative follicular lymphomas.
Salaverria I; Weigert O; Quintanilla-Martinez L
Blood Adv; 2023 Sep; 7(18):5258-5271. PubMed ID: 37561599
[TBL] [Abstract] [Full Text] [Related]
8. The cardiac glycoside ZINC253504760 induces parthanatos-type cell death and G2/M arrest via downregulation of mek1/2 phosphorylation in leukemia cells.
Zhou M; Boulos JC; Klauck SM; Efferth T
Cell Biol Toxicol; 2023 Dec; 39(6):2971-2997. PubMed ID: 37322258
[TBL] [Abstract] [Full Text] [Related]
9. A case report of a blueberry muffin baby caused by congenital self-healing indeterminate cell histiocytosis.
Koster SBL; Vinke ME; van den Bos C; van Heel WJM; Kranendonk MEG; Natté R; van Tuyll van Serooskerken AM
BMC Pediatr; 2023 Mar; 23(1):111. PubMed ID: 36890472
[TBL] [Abstract] [Full Text] [Related]
10. Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update.
Roskoski R
Pharmacol Res; 2023 Jan; 187():106552. PubMed ID: 36403719
[TBL] [Abstract] [Full Text] [Related]
11. Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors.
Lebedev TD; Khabusheva ER; Mareeva SR; Ivanenko KA; Morozov AV; Spirin PV; Rubtsov PM; Snezhkina AV; Kudryavtseva AV; Sorokin MI; Buzdin AA; Prassolov VS
J Biol Chem; 2022 Aug; 298(8):102226. PubMed ID: 35787369
[TBL] [Abstract] [Full Text] [Related]
12. TRAF3 alterations are frequent in del-3'IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features.
Pérez-Carretero C; Hernández-Sánchez M; González T; Quijada-Álamo M; Martín-Izquierdo M; Santos-Mínguez S; Miguel-García C; Vidal MJ; García-De-Coca A; Galende J; Pardal E; Aguilar C; Vargas-Pabón M; Dávila J; Gascón-Y-Marín I; Hernández-Rivas JÁ; Benito R; Hernández-Rivas JM; Rodríguez-Vicente AE
Am J Hematol; 2022 Jul; 97(7):903-914. PubMed ID: 35472012
[TBL] [Abstract] [Full Text] [Related]
13. B-cell receptor signaling induces proteasomal degradation of PDCD4 via mek1/2 and mTORC1 in malignant B cells.
Taylor J; Wilmore S; Marriot S; Rogers-Broadway KR; Fell R; Minton AR; Branch T; Ashton-Key M; Coldwell M; Stevenson FK; Forconi F; Steele AJ; Packham G; Yeomans A
Cell Signal; 2022 Jun; 94():110311. PubMed ID: 35306137
[TBL] [Abstract] [Full Text] [Related]
14. Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial.
Menne T; Slade D; Savage J; Johnson S; Irving J; Kearns P; Plummer R; Shenton G; Veal GJ; Vormoor B; Vormoor J; Billingham L
BMJ Open; 2022 Mar; 12(3):e059872. PubMed ID: 35246426
[TBL] [Abstract] [Full Text] [Related]
15. Advances in the Treatment of Hairy Cell leukemia Variant.
Tran J; Gaulin C; Tallman MS
Curr Treat Options Oncol; 2022 Jan; 23(1):99-116. PubMed ID: 35178674
[TBL] [Abstract] [Full Text] [Related]
16. ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells.
Valdez BC; Murray D; Yuan B; Nieto Y; Popat U; Andersson BS
Oncotarget; 2022; 13():319-330. PubMed ID: 35154579
[TBL] [Abstract] [Full Text] [Related]
17. Fine-tuning of MEK signaling is pivotal for limiting B and T cell activation.
Houde N; Beuret L; Bonaud A; Fortier-Beaulieu SP; Truchon-Landry K; Aoidi R; Pic É; Alouche N; Rondeau V; Schlecht-Louf G; Balabanian K; Espéli M; Charron J
Cell Rep; 2022 Jan; 38(2):110223. PubMed ID: 35021072
[TBL] [Abstract] [Full Text] [Related]
18. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update.
Roskoski R
Pharmacol Res; 2022 Jan; 175():106037. PubMed ID: 34921994
[TBL] [Abstract] [Full Text] [Related]
19. Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL.
Sasaki K; Yamauchi T; Semba Y; Nogami J; Imanaga H; Terasaki T; Nakao F; Akahane K; Inukai T; Verhoeyen E; Akashi K; Maeda T
Blood; 2022 Feb; 139(5):748-760. PubMed ID: 34587248
[TBL] [Abstract] [Full Text] [Related]
20. A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell Lymphoma and Histiocytic/Dendritic Cell Tumor.
Cheng F; Yu F; Wang X; Huang K; Lu H; Wang Z
Int J Surg Pathol; 2021 Dec; 29(8):906-914. PubMed ID: 33939500
[TBL] [Abstract] [Full Text] [Related]
[Next]
